Promedior to Present Clinical Data on Lead Drug Candidate, PRM-151, in Patients With IPF at the ATS 2013 Annual Meeting
5/16/2013 11:20:26 AM
More...
|
Promedior to Present Clinical Data on Lead Drug Candidate, PRM-151, in Patients With IPF at the American Thoracic Society 2013 Annual Meeting
5/16/2013 11:00:42 AM
More...
|
Promedior to Present Clinical Data on Lead Drug Candidate, PRM-151, in Patients with IPF at the ATS 2013 Annual Meeting
5/16/2013 10:14:08 AM
More...
|
Promedior Opens New Office and Laboratories in Lexington, Mass.
12/17/2012 9:41:19 AM
More...
|
Promedior Appoints Elizabeth Trehu, M.D., as Chief Medical Officer
10/15/2012 9:50:26 AM
More...
|
Promedior Closes $24.5 Million Series D
10/15/2012 6:58:14 AM
More...
|
Promedior Moves Fibrosis Pipeline to Boston, Hires Shire plc Vet as CEO
5/15/2012 7:50:29 AM
More...
|
Promedior Announces Presentation of Preclinical Data at Association for Research in Vision & Ophthalmology Demonstrating that Pentraxin-2 Suppressed Fibrosis, Neovascularization, and Vascular Leakage
5/7/2012 9:53:44 AM
More...
|
Promedior Announces Presentation of Data at Association for Research in Vision & Ophthalmology Demonstrating that Pentraxin-2 Suppresses Fibrosis, Neovascularization, and Vascular Leak in Retinal Disease Models
5/1/2012 10:51:54 AM
More...
|
Promedior Scores $21.5 Million for Fibrotic Diseases
3/8/2012 7:20:33 AM
More...
|
|